Skip to content

Trinity Nuclein Series C Investors

4 viewers · 30d

Total raised

$2.3M

1 filing since 2025 · latest Fund filed

Cumulative raised
LAST ROUND
Fund · $2.3M
ROUNDS
1
INVESTORS
23
FOUNDED
2025
HQ
Southlake, TX
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
4

AI overview

Updated

Nuclein is an innovative medical device company that specializes in the development of rapid diagnostic testing technologies. Founded in 2017 and based in Austin, Texas, Nuclein addresses the critical need for fast, accurate, and accessible testing for infectious diseases.

What sets it apart

Nuclein stands out by providing lab-quality PCR test results in just 15 minutes at the point of care, making advanced testing accessible and efficient.

Funding history

1 round
Fund+1Feb 18, 2025 · $75K min
Form D
+$2.3M$2.3M total

Latest SEC filings

via EDGAR · CIK 0002054957
Form D · Feb 18, 2025View on EDGAR

Products

1 tracked

DASH® Rapid PCR System

Rapid Diagnostics

The DASH® Rapid PCR System is a cutting-edge diagnostic tool that enables healthcare professionals to deliver lab-quality PCR test results in a rapid timeframe of just 15 minutes. Designed for use at the point of care, this system significantly enhances the speed of infectious disease diagnosis, providing immediate results to both practitioners and patients.

  • Low-cost testing
  • Highly sensitive and specific results
  • Robust multiplexing capabilities across various sample types
  • Less than one minute of hands-on time required